Denali Therapeutics (NASDAQ:DNLI) Sets New 1-Year Low at $14.56

Denali Therapeutics Inc. (NASDAQ:DNLI)’s stock price reached a new 52-week low on Thursday . The stock traded as low as $14.56 and last traded at $14.79, with a volume of 172121 shares traded. The stock had previously closed at $15.56.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. UBS Group lowered their target price on shares of Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday, April 9th. The Goldman Sachs Group dropped their target price on shares of Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday, February 29th. Wedbush reaffirmed an “outperform” rating and set a $31.00 price target on shares of Denali Therapeutics in a research note on Wednesday, February 28th. Finally, HC Wainwright lowered their price target on Denali Therapeutics from $105.00 to $95.00 and set a “buy” rating for the company in a report on Wednesday, February 28th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Denali Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $41.22.

Denali Therapeutics Stock Performance

The firm has a market capitalization of $2.20 billion, a PE ratio of -14.29 and a beta of 1.33. The stock has a fifty day moving average price of $19.03 and a 200-day moving average price of $19.08.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Tuesday, February 27th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.81) by ($0.05). Denali Therapeutics had a negative net margin of 36.51% and a negative return on equity of 13.50%. During the same period in the previous year, the business posted ($0.75) earnings per share. Research analysts expect that Denali Therapeutics Inc. will post -2.61 earnings per share for the current fiscal year.

Insider Activity at Denali Therapeutics

In other Denali Therapeutics news, Director Vicki L. Sato sold 1,666 shares of Denali Therapeutics stock in a transaction on Monday, April 15th. The shares were sold at an average price of $18.29, for a total value of $30,471.14. Following the transaction, the director now directly owns 118,043 shares of the company’s stock, valued at $2,159,006.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Steve E. Krognes sold 92,500 shares of Denali Therapeutics stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $20.50, for a total value of $1,896,250.00. Following the completion of the sale, the director now directly owns 47,341 shares in the company, valued at approximately $970,490.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Vicki L. Sato sold 1,666 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $18.29, for a total transaction of $30,471.14. Following the sale, the director now directly owns 118,043 shares in the company, valued at approximately $2,159,006.47. The disclosure for this sale can be found here. Insiders sold 110,955 shares of company stock valued at $2,218,802 over the last 90 days. Insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On Denali Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. CWM LLC raised its stake in Denali Therapeutics by 216.7% in the 4th quarter. CWM LLC now owns 2,011 shares of the company’s stock worth $43,000 after acquiring an additional 1,376 shares during the last quarter. Assetmark Inc. raised its stake in shares of Denali Therapeutics by 49.1% in the third quarter. Assetmark Inc. now owns 2,148 shares of the company’s stock worth $44,000 after purchasing an additional 707 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Denali Therapeutics by 48.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock worth $53,000 after purchasing an additional 807 shares during the period. Fisher Asset Management LLC purchased a new stake in Denali Therapeutics in the fourth quarter valued at approximately $59,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Denali Therapeutics by 96.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,526 shares of the company’s stock worth $73,000 after buying an additional 1,732 shares during the period. 92.92% of the stock is currently owned by institutional investors and hedge funds.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.